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bTATE-OF-THE-ART PAPER1683Antithrombotic Therapy in the Elderlyavide Capodanno, Dominick J. Angiolillo
lthough the benefits of antithrombotic medications are well established, elderly patients
ay be more vulnerable to adverse bleeding events. Capodanno and Angiolillo review
he literature to explore this issue and determine if certain medications should be used
referentially. The increased risk of bleeding appears to be related to distinct pharmacokinetic
nd pharmacodynamic responses, as well as drug–drug interactions due to polypharrmacy.
nfortunately, many of the pivotal studies have excluded elderly patients. The present paper
rovides an overview of the currently available evidence on the use of specific antithrombotic
herapies in elderly patients.TATE-OF-THE-ART PAPER1693Immunologic and Inflammatory Reactions to Exogenous Stem Cells. Maximilian Buja, Deborah Vela
linical trials with allogeneic stem cells are now underway, based on the premise that stem
ells and precursor cells do not provoke an immunologic host response. Buja and Vela review
vidence indicating that stem cells may provoke a reaction, especially when delivered to
nflamed tissue, such as acutely infarcted myocardium. The immune-mediated reaction to
llogeneic and xenogeneic stem cells may be beneficial (e.g., increased paracrine activity) or
etrimental (e.g., accelerated removal of stem cells). Further studies are needed to determine
he net effect of immune-mediated responses to nonself stem cells, but these cells should not
e considered immunologically inert.(continued on page A-26)
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hLINICAL TRIALS1701Telmisartan Reduces Mortality in CHF Patients on Hemodialysisennaro Cice, Attilio Di Benedetto, Salvatore D’Isa, Antonello D’Andrea, Daniele Marcelli,
manuele Gatti, Raffaele Calabrò
ice and colleagues hypothesized that hemodialysis patients with chronic heart failure (CHF)
n standard therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and a beta-
locker may benefit from the addition of an angiotensin receptor blocker (ARB) because
CE-Is are removed by dialysis, whereas telmisartan is not. Over 300 subjects on chronic
emodialysis with CHF (left ventricular ejection fraction 40%) were randomized to
elmisartan or placebo in addition to ACE-I therapy. At 3 years, telmisartan significantly
educed all-cause mortality, cardiovascular death, and hospital admission for CHF, with
azard ratios from 0.38 to 0.51. Telmisartan significantly improves outcomes in patients on
hronic hemodialysis who have systolic dysfunction.ditorial Comment: Ilke Sipahi, James C. Fang, p. 1709ARDIOVASCULAR RISK1712Biomarkers May Identify Those at Risk for Incident HF and AF. Gustav Smith, Christopher Newton-Cheh, Peter Almgren, Joachim Struck, Nils G. Morgenthaler,
ndreas Bergmann, Pyotr G. Platonov, Bo Hedblad, Gunnar Engström, Thomas J. Wang,
lle Melander
mith and colleagues used long-term data from over 5,000 subjects to determine if a panel
f biomarkers could help to identify which subjects are likely to develop heart failure
HF) or atrial fibrillation (AF). The panel consisted of 6 biomarkers reflecting diverse
athophysiological pathways. During a mean follow-up of 14 years, N-terminal pro–B-type
atriuretic peptide, C-reactive protein (CRP), and midregional pro-atrial natriuretic peptide
MR-proANP) each predicted incident HF independently of conventional risk factors.
R-proANP and CRP independently predicted AF. Natriuretic peptides modestly improvehe ability to identify subjects at risk for HF and AF beyond traditional risk factors.EART FAILURE1720Depression Modifies -Adrenergic–Associated Leukocyte Mobilization in HF Patients
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-0.3 HFaura S. Redwine, Petra H. Wirtz, Suzi Hong, Jos Bosch, Michael G. Ziegler, Barry Greenberg,
aul J. Mills
edwine and colleagues sought to determine if depression alters the sensitivity of peripheral
lood mononuclear cells (PBMCs) to -adrenergic stimulation in patients with heart failure
HF). Chemotaxis (CTX) to isoproterenol was measured at rest and following exercise in HF
nd control patients, who were also assessed for symptoms of depression. In HF patients,
epressive symptom severity was associated with greater CTX following exercise. Higher basal
orepinephrine serum levels were also associated with increased CTX after exercise. These
esults indicate that HF patients with higher depression symptoms and norepinephrine levels
ave increased PBMC migration, which could affect cardiac remodeling.(continued on page A-29)
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1728anine Model Offers Insight Into the Roles of the Left Atrial Roof
and Pulmonary Veins in Propagating and Initiating AFunihiro Nishida, Jean-François Sarrazin, Akira Fujiki, Hakan Oral, Hiroshi Inoue, Fred Morady,
tanley Nattel
ishida and colleagues studied the electrophysiological consequences of pulmonary vein
ncircling ablation (PVEA) and linear left atrial roof ablation (LARA) for atrial fibrillation
AF). Atrial tachypacing was used to create an AF substrate in dogs. PVEA and LARA were
pplied in randomized order. PVEA failed to terminate AF or affect AF duration, but
ecreased AF vulnerability to single extrastimuli. LARA frequently terminated AF and
educed AF duration without affecting AF vulnerability. Both PVEA and LARA have
eneficial but limited effects in this canine model.ditorial Comment: J. Paul Mounsey, p. 1737ONGENITAL HEART DISEASE1740Aortic Valve Reinterventions After Balloon Aortic Valvuloplasty for Congenital ASavid W. Brown, Amy E. Dipilato, Erin C. Chong, James E. Lock, Doff B. McElhinney
rown and colleagues evaluated the long-term results of transcatheter balloon aortic
alvuloplasty for congenital aortic stenosis (AS). Median follow-up was 9.3 years in the 500
ubjects who had a median age of 2.4 years at the time of the initial procedure. Peak AS
radients decreased significantly after dilation, and acute post-dilation aortic regurgitation
AR) was moderate or greater in 14%. Survival free from any aortic valve reintervention was
9% at 1 year, 72% at 5 years, 54% at 10 years, and only 27% at 20 years. While
ranscatheter aortic valvuloplasty is effective for acute relief of congenital AS, these patients
re likely to require a subsequent aortic valve intervention.ditorial Comment: John P. Cheatham, Ralf J. Holzer, p. 1750EART DISEASE IN WOMEN
1752omplicated Relationship Between
Bisphosphonates and Vascular and Valvular Calcificationammy Elmariah, Joseph A. C. Delaney, Kevin D. O’Brien, Matthew J. Budoff, Jens Vogel-Claussen,
alentin Fuster, Richard A. Kronmal, Jonathan L. Halperin
isphosphonates are primarily used in the management of osteoporosis. Nitrogen-containing
isphosphonates (NCBPs) inhibit farnesylpyrophosphate synthase, an enzyme in the
evalonate pathway distal to 3-hydroxy-3-methyl-glutaryl-CoA reductase, the site of statin
ction, and several pharmacologic effects are common to both NCBPs and statins. Elmariah
nd colleagues investigated the relationship between NCBPs and cardiovascular calcification
sing data from the MESA (Multi-Ethnic Study of Atherosclerosis). After adjusting for
everal risk factors, NCBP use was associated with a lower prevalence of cardiovascular
alcification in women 65 years of age, whereas calcification was more prevalent in NCBP
sers 65 years of age. These results suggest a complex relationship between NCBPs and
ardiac calcification that merits further investigation.
